SWSara E. Walton

Sara E. Walton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara E. Walton has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantification of kratom alkaloids mitragynine, 7-hydroxy mitragynine, mitragynine pseudoindoxyl, and dihydro-7-hydroxy mitragynine in forensic casework and medicolegal death investigations

    by Lauren K Eccarius, Sara E Walton, Donna M Papsun, Barry K Logan, Alex J Krotulski

    Mitragynine (MG) is the primary psychoactive component of the kratom plant (Mitragyna speciosa). 7-Hydroxy mitragynine (7OH-MG) is found naturally in the plant but in small amounts (<2%). MG is metabolized to 7OH-MG and further to mitragynine pseudoindoxyl (MP), with the latter documented via in vitro enzymatic activity. Lack of scheduling and oversight has caused unregulated markets to proliferate with gas stations, smoke shops, and online retailers selling semi-synthetic formulations of these alkaloids under the umbrella term “kratom,” though distinct from botanical kratom. Products containing 7OH-MG, MP, and synthetically derived dihydro-7-hydroxy mitragynine (DH-7OH-MG, aka MGM-15) exhibit greater potencies and activities at the µ-opioid receptor compared to MG and are now highly implicated in intoxications and deaths. These alkaloids present complex analytical and interpretive challenges due to their isomeric forms, incompatibility with certain extraction and instrumental techniques promoting analyte interconversion, instability in blood, and lack of published concentration ranges. A quantitative high-resolution mass spectrometry method for MG, 7OH-MG, MP, and DH-7OH-MG, which prevents interconversion and separates isomers, is presented herein along with stability data and concentrations from more than 200 authentic cases. MG, MP, and DH-7OH-MG were relatively stable in blood, whereas 7OH-MG decreased quickly and by 89% over 112 days with a concurrent increase in MP. In a case subset (n = 139), mean ± SD concentrations in blood were 146 ± 477 ng/ml for 7OH-MG (median: 58 ng/ml, range: 0–5000 ng/ml) and 194 ± 239 ng/ml for MP (median: 120 ng/ml, range: 4.8–1900 ng/ml). In a second subset (n = 17), the mean ± SD DH-7OH-MG (MGM-15) concentration was 324 ± 669 ng/ml (median: 170 ng/ml, range: 50–2900 ng/ml). Testing for kratom alkaloids is currently extremely limited and/or subject to potential inaccuracies due to interconversion, leaving adverse events and fatalities under-investigated. Continued vigilance is needed as the kratom alkaloid product landscape rapidly evolves.

  • Intoxications and fatalities associated with the ingestion of the novel synthetic cathinone, N -isopropyl butylone

    by Munchelou M Gomonit, Sara E Walton, Michael T Truver, Chris W Chronister, Donna M Papsun, Alex J Krotulski, Bruce A Goldberger, Barry K Logan

    Synthetic cathinones represent an expanding class of novel psychoactive substances (NPS), with their proliferation largely driven by international drug control measures and the rapid cycling of structural analogues designed to circumvent legislative scheduling. Following the international control of N, N-dimethylpentylone (DMP) in 2024, N-isopropyl butylone (NiPB) was increasingly detected in forensic toxicological casework as the prevalence of DMP declined. However, limited data currently exist regarding NiPB’s concentration ranges in forensic investigations. This report describes a validated liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS) method for the quantitation of NiPB in biological specimens, which was applied to the analysis of drugged driving (n = 1) and postmortem (n = 15) cases. The driving under the influence of drugs case yielded a NiPB blood concentration of 16 ng/mL, whereas the remaining 15 cases demonstrated blood concentrations ranging from <1 to 1400 ng/mL. For one case, NiPB was quantitated in blood, vitreous fluid, and urine, with concentrations of 18, 17, and 2200 ng/mL, respectively. Polydrug use was observed for all cases and frequently involved fentanyl (75%), cocaine and/or methamphetamine (69%), other synthetic cathinones (25%), ethanol (31%), and additional NPS such as bromazolam (19%) and MDMB-4en-PINACA (13%). Concentrations overlapped between antemortem and postmortem cases and were comparable to those reported for structurally related beta-keto methylenedioxyamphetamines, suggesting that members of this analogue class may share similar patterns of use and toxicological profiles. Although NiPB was identified as a contributing factor in several fatalities, the lack of pharmacological and toxicological data limits further interpretation of measured concentrations and the extent of its contribution to these fatal outcomes. Additional studies incorporating paired central and peripheral blood specimens are warranted to better characterize potential postmortem redistribution and its impact on NiPB blood concentration interpretation. Overall, this case series addresses a critical literature gap on NiPB by providing analytical and interpretive data to support forensic laboratories as NiPB identifications increase within the evolving NPS stimulant market.

  • Open Access

    Micro‐QuEChERS Extraction for Broad‐Spectrum LC‐QQQ‐MS Quantification of Nitazene Analogs in Plasma: A Validated Method With Casework Application

    by Karla A. O. Souza, Náthaly C. B. F. Santos, Rafael Lanaro, Sara E. Walton, Alex J. Krotulski, Barry K. Logan, Mauricio Yonamine, Jose Luiz Costa

    Nitazenes are highly potent synthetic opioids of increasing concern in clinical and forensic toxicology, thus underscoring the need for sensitive and selective analytical methods for biological specimens. This study describes the development and validation of an LC–MS/MS method for the quantification of nitazene analogs and related metabolites in plasma using micro‐QuEChERS sample preparation. The validated concentration range was 0.05–20 ng/mL, with coefficients of determination R 2 > 0.99. The limit of detection (LOD) was 0.025 ng/mL, and the lower limit of quantification (LLOQ) was 0.05 ng/mL. Bias ranged from −2.6% to 15.7%, within‐run precision from 3.4% to 12.7%, and between‐run precision from 4.4% to 14.9%, as evaluated at three quality control levels. Matrix effects and recovery were analyte‐dependent but compatible with satisfactory overall validation performance. No interferences or carryover were observed. Method applicability was demonstrated in an authentic intoxication case, in which N ‐pyrrolidino protonitazene was quantified at 1.4 ng/mL, representing, to our knowledge, the first clinical case reported in Brazil. The case was clinically characterized by severe opioid toxicity requiring repeated naloxone administration. The proposed method combined low sample volume, simple sample preparation, and suitable analytical performance for targeted analysis of emerging nitazene compounds. These findings support the use of micro‐QuEChERS and LC–MS/MS as a practical approach for targeted nitazene quantification in clinical and forensic toxicology.

  • Top Cited Papers

    Pharmacokinetics of xylazine and fentanyl in patients presenting to the emergency department after non-fatal opioid overdose

    by Alex J. Krotulski, Michael H. Baumann, Brittany P. Chapman, Patricia Mae E. Martinez, John P. Broach, John Nguyen, Deborah Olabisi, Jyothi Polackal, Sara E. Walton, Brianna N. Stang, et al.


  • Comprehensive toxicological characterization and quantitation of drugs identified among nonfatal opioid and stimulant overdose presentations to US emergency departments

    by Brianna N Stang, Jessica T Kent, Sara E Walton, Kim Aldy, Rachel Culbreth, Alyssa Falise, Sharan Campleman, Barry K Logan, Jeffrey Brent, Paul Wax, et al.

    Drug overdoses presenting to emergency departments (EDs) remain poorly characterized largely due to limitations resulting from constraints of hospital toxicology testing. This presents significant challenges for forensic and public health communities, as this population of primarily nonfatal overdoses is frequently not included with other data streams (e.g. fatalities, recreational drug markets), producing incomplete national and regional knowledge. To combat this issue, we performed a comprehensive toxicological analysis on patients presenting to EDs with suspected opioid or stimulant overdose. The Toxicology Investigators Consortium (ToxIC) implemented the Drug Toxico-Surveillance Reporting System at 17 healthcare institutions across the United States between April 2023 and September 2024, 995 patients (mortality rate = 1.0%, n = 10) were enrolled, and blood specimens were collected and analyzed at the Center for Forensic Science Research and Education. All specimens underwent blood alcohol analysis, comprehensive screening of over 1,200 xenobiotics, and quantitation for drugs of interest. At least one xenobiotic was detected in 992 specimens. Most frequently observed drugs include fentanyl (n = 713, mean: 8.0 ± 11 ng/mL), methamphetamine (n = 380, mean: 170 ± 210 ng/mL), and cocaine (n = 306, mean: 7.6 ± 15 ng/mL). There were 629 detections of 43 unique novel psychoactive substances (NPS), including potent alpha-2-agonists xylazine (n = 249, mean: 14 ± 29 ng/mL) and medetomidine (n = 31, mean: 1.5 ± 1.8 ng/mL). Regional trends observed include increased prevalence of methamphetamine in the western and central United States, alpha-2-agonists in the eastern United States, and greater NPS diversity in the eastern United States. Traditional opioids and stimulants were generally detected at higher mean concentrations than their more potent NPS counterparts. Quantitative data varies in comparison to literature on postmortem and driving under the influence of drugs cases. This is the first study to analyze blood specimens and provide quantitative data from a large sample of primarily nonfatal opioid/stimulant related overdoses.


  • In vitro metabolic profile characterization for synthetic cannabinoids MDMB-BINACA, MDMB-PICA, and AB-CHMINACA

    by Lauren K Eccarius, Brianna N Stang, Sara E Walton, Alex J Krotulski, Barry K Logan

    The illicit synthetic cannabinoid receptor agonist (SCRA) market has experienced multiple changes since its appearance in the 2010s and, most recently, in response to a class-wide SCRA ban imposed by China in 2021. The reemergence of “older” SCRAs, such as the highly potent indole- and indazole-3-carboxamide-containing drugs, has occurred due to the sale of unregulated precursors on grey-market and dark websites. This shift poses a significant threat to public health, and recent intoxication outbreaks associated with these types of SCRAs demonstrate the need for further toxicological research to aid in better understanding their metabolism and appropriate targets for toxicological testing. Testing for metabolites can extend the detection window of SCRAs as parent drugs are rapidly metabolized and present at low or potentially undetectable concentrations in biological samples, including urine. In these instances, metabolites may be more sensitive biomarkers of SCRA use. This study characterized the metabolites for the synthetic cannabinoids MDMB-BINACA (also known as MDMB-BUTINACA), MDMB-PICA, and AB-CHMINACA via in vitro human liver microsome (HLM) incubation and analysis by liquid chromatography–quadrupole time-of-flight mass spectrometry (LC–QTOF-MS). Biotransformations observed in this study included ester and amide hydrolysis, oxidation, carboxylation, and dealkylation. Nine metabolites were identified for MDMB-BINACA, five of which were verified through retrospective analysis of authentic samples. Nine metabolites were also identified for both MDMB-PICA and AB-CHMINACA, with two metabolites of AB-CHMINACA verified in authentic samples. Characterization of the metabolism of these potent drugs allows for the use of the identified biomarker to improve forensic toxicology analyses and interpretation, especially when the use of synthetic cannabinoids is suspected.


  • Open Access

    Rapid LC–QTOF–MS screening method for semi-synthetic cannabinoids in whole blood

    by Willi Schirmer, Sara E Walton, Wolfgang Weinmann, Stefan Schürch, Barry K Logan, Alex J Krotulski

    Semi-synthetic cannabinoids are a class of new psychoactive substances (NPSs) with structural similarities to the main psychoactive phytocannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) found in Cannabis sativa L. The first semi-synthetic cannabinoids, which were used as legal substitutes for marijuana, were Δ8-tetrahydrocannabinol (Δ8-THC) and hexahydrocannabinol (HHC). Δ8-THC emerged around 2019 on the recreational drug market in the United States after it became legal due to an ambiguity in the Agricultural Improvement Act 2018 (Farm Bill 2018). It was never legal outside the United States as the isomers of THC are regulated in the United Single Convention on Narcotic Drugs from 1971. HHC, a hydrogenated derivative of THC, followed as a legal substitute on the European recreational drug market. Many countries already placed HHC in their narcotic substance law, which led to the emergence of other structurally related derivatives of THC. An existing rapid screening method for the qualitative analysis of various new psychoactive substances was expanded for semi-synthetic cannabinoids in whole blood using a LC–QTOF–MS system. This method was validated for 24 different phytocannabinoids and semi-synthetic cannabinoids in blood. Recovery rates of the analytes from a liquid–liquid-extraction ranged from 87% to 118%, matrix effects ranged from 24% to 93%, and limits of detection (LOD) ranged from 0.8 to 16 ng/mL.


  • Medetomidine quantitation and enantiomer differentiation in biological specimens collected after fatal and non-fatal opioid overdoses

    by Sara E Walton, Brianna N Stang, Sherri Kacinko, Donna M Papsun, Barry K Logan, Alex J Krotulski

    Medetomidine is an alpha-2 agonist and non-opioid sedative. Its presence in illicit fentanyl and heroin drug supplies poses significant risks to user health caused by cardiac effects and sedation. Medetomidine exists in two enantiomeric forms: dexmedetomidine and levomedetomidine. Dexmedetomidine is used in humans in medical settings, while dexmedetomidine alone and a racemic mixture of dexmedetomidine and levomedetomidine are used in animals in veterinary settings. Little information is known about circulating blood concentrations of medetomidine or its enantiomers in humans in situations involving synthetic opioids (e.g. fentanyl) and other sedatives (e.g. xylazine, benzodiazepines). A new toxicological workflow using liquid chromatography–tandem quadrupole mass spectrometry (LC–QQQ-MS) was developed and validated for the quantitation of medetomidine and the qualitative enantiomeric separation of dexmedetomidine and levomedetomidine. The assays were applied to a case series of 100 authentic specimens from emergency department admissions and forensic postmortem investigations containing medetomidine, fentanyl, xylazine, and metabolites, among other substances. Medetomidine blood concentrations in non-fatal overdoses ranged 0.1–16 ng/mL (median: 1.5 ng/mL) and in fatal overdoses ranged 0.1–32 ng/mL (median: 0.31 ng/mL). Xylazine was co-detected in 76% of cases with higher median concentrations: 8.3 ng/mL (non-fatal) and 15 ng/mL (fatal). Fentanyl was co-detected in 93% of cases with median concentrations of 5.2 ng/mL (non-fatal) and 21 ng/mL (fatal). Dexmedetomidine and levomedetomidine were identified in 90% of cases; the remaining cases were confirmed or suspected medical-setting administration of dexmedetomidine. These findings demonstrate that medetomidine is arising from veterinary or clandestine sources, and we hypothesize the latter. Recreational medetomidine use causes adverse effects such as profound bradycardia and heightened sedation, especially when combined with fentanyl and xylazine. Forensic laboratories must remain aware of adulterants, like medetomidine, appearing in traditional opioid products (e.g. fentanyl, heroin), updating testing methods to capture these emerging adulterants in real-time.